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Purpose: Angiogenesis is pivotal in tumor development. Vascular endothelial growth factor-
A (VEGF-A) is considered one of the most important angiogenic factors, but lately several 
microRNAs (miRs) have been associated with vascular development. miR-126 has been 
related to tumor angiogenesis and in the regulation of VEGF-A. We aimed to investigate the 
prognostic impact of miR-126 and its co-expression with VEGF-A in non-small cell lung 
cancer (NSCLC) patients.   
Patients and methods: Tumor tissue samples from 335 resected stage I to IIIA NSCLC 
patients were obtained and tissue microarrays (TMAs) were constructed with four cores from 
each tumor specimen. VEGF-A expression was evaluated by immunohistochemistry and in 
situ hybridization was used to evaluate the expression of miR-126. 
Results: In the total material, miR-126 was a significant negative prognostic factor in both 
univariate (P=0.005) and multivariate analyses (HR 1.6, 95% CI 1.1–2.5, P=0.028). Stratified 
by histology, miR-126 was only significant in squamous cell carcinomas (univariate; 
P<0.001, multivariate; HR 2.6, CI95% 1.5–4.5, P<0.001). Stratified by lymph node status, 
miR-126 was significant only in the lymph node positive subgroup (univariate; P<0.001, 
multivariate; HR 3.4, CI95%1.8–6.3, P<0.001). High miR-126 expression correlated 
significantly with high VEGF-A expression (P=0.037). The co-expression of miR-126 and 
VEGF-A had a significant prognostic impact (P=0.002), with 5-year survival rates of 68%, 
51% and 42% for low/low (n=150), mixed combinations (n=129) and high/high (n=35) 
expression, respectively. 
Conclusion: miR-126 is a strong and independent negative prognostic factor in NSCLC, and 
its prognostic impact appears related primarily to histology and nodal status. 
































































Lung cancer is the leading cause of cancer-related deaths in both women and men, and 
approximately 80% of the patients have non-small cell lung cancer (NSCLC). Because lung 
cancer is a deadly disease with a 5-year survival rate of less than 15%, a prognostic 
assessment of these patients is essential for treatment stratification.
1,2
  
MicroRNA (miRNAs or miRs) are regulatory, non-coding RNAs about 21-23 
nucleotides in length and are expressed at specific stages of tissue development, and have 
large-scale effects on the expression of a variety of genes at a post-transcriptional level. miRs 




Angiogenesis is defined as the growth of endothelial sprouts of pre-existing post-
capillary venules and regarded as a hallmark in cancer development.
5,6
 Evidence is emerging 
that miRs are important players in endothelial cell biology and tumor angiogenesis.
5,7
  
Dynamic changes in miR expression in response to growth factor stimulation or hypoxia 
imply that miRs are an integral component of the angiogenic program.
7
  
miR-126, a key positive regulator, promotes angiogenesis in response to angiogenic 
growth factors, such as vascular endothelial growth factor-A (VEGF-A). This is done by 
repressing negative regulators of signal transduction pathways.
7
 In this context miR-126 work 
as an oncogene, but several studies have shown that miR-126 is down-regulated in different 
malignancies and is a potential tumor suppressor.
8-11
 miR-126 has also been shown to be 
down-regulated in lung cancer and in vitro and murine NSCLC studies have indicated that 
miR-126 restoration may down-regulate VEGF-A.
12-14
  
These contradictory results may indicate that miR-126 have several functions and is 
highly tissue specific. NSCLC classification according to histology and nodal status are two 
of the most important determinants for NSCLC treatment strategies.
15,16 
 However, a 






























































considerable variability in prognosis has been observed for subsets of patients with the same 
histological or clinical features. Consequently, the clinical incorporation of predictive and 
prognostic molecular biomarkers together with traditional cancer staging should improve the 
management of patients with NSCLC.  
Considering the previous conflicting results regarding impact of miR-126, our 
hypothesis is that miR-126 may have different prognostic impacts within NSCLC subgroups. 
In an unselected NSCLC cohort of 335 patients,
17
 we aimed to explore possible prognostic 
roles by miR-126 in all NSCLC cases and subgroups according to histology and nodal status, 
using in situ hybridization and a high throughput TMA platform. Further, we examined the 













































































PATIENTS AND METHODS 
Patients and Clinical Samples 
Primary tumor tissues from anonymized patients diagnosed with NSCLC pathologic stage I to 
IIIA at the University Hospital of North Norway (UNN) and Nordland Central Hospital 
(NLCH) from 1990 through 2004 were used in this retrospective study. In total, 371 patients 
were registered from the hospital database. Of these, 36 patients were excluded from the study 
due to: (i) Radiotherapy or chemotherapy prior to surgery (n = 10); (ii) Other malignancy 
within five years prior to NSCLC diagnosis (n = 13); (iii) Inadequate paraffin-embedded fixed 
tissue blocks (n = 13). Adjuvant chemotherapy was not introduced in Norway during this 
period (1990 – 2004). Thus, 335 patients with complete medical records and adequate 
paraffin-embedded tissue blocks were eligible.  
This report includes follow-up data as of November 30, 2008. The median follow-up 
of survivors was 86 (range 48-216) months. The tumors were staged according to the new 7th 
edition of TNM in Lung Cancer and histologically subtyped and graded according to the 
World Health Organization guidelines.
16,18
 Regarding N-status, ipsilateral peribronchial or 
hilar nodes and intrapulmonary nodes are defined as N1, while N2 includes ipsilateral 
mediastinal or subcarinal nodes. The term N+ (lymph node metastasis present) includes both 
N1 and N2. The National Data Inspection Board and The Regional Committee for Research 
Ethics approved the study. 
 
Microarray construction 
All lung cancer cases were histologically reviewed by two pathologists (S.A.S. and K.A.S.) 
and the most representative areas of viable tumor cells were carefully selected. The TMAs 
were assembled using a tissue-arraying instrument (Beecher Instruments, Silver Springs, 
MD). The Detailed methodology has been previously reported.
17
 Briefly, we used a 0.6 mm 






























































diameter stylet, and the study specimens were routinely sampled with four replicate core 
samples (different areas) of tumor tissue. In addition, normal lung tissue localized distant 
from the primary tumor, and one slide with normal lung tissue samples from 20 patients 
without a cancer diagnosis, were stained. Multiple 4-µm sections were cut with a Micron 
microtome (HM355S) and used for in situ hybridization analysis.  
 
In Situ Hybridization (ISH) 
The method used for in situ hybridization is based on a protocol developed by Nuovo 
et al,
19
 with minor adjustments. 
Double-DIG labeled (Exiqon, Vedbaek, Denmark) miRCURY LNA detection probes 
were used for visualization of the miRNA hsa-miR-126 and included a scrambled probe as 
negative control and U6 as a positive control. 
Briefly, we placed 4 µm sections from the TMA blocks in a heater at 59
 o
C over night 
to make the cores attach to the slide. Sections were deparaffinised with xylene (2x5 min), 
rehydrated with ethanol (100 – 50 – 25% for 5 min each), and treated with DEPC water for 1 
min. Protease treatment was performed with pepsin solution (Dako, Glostrup, Denmark) at 
1.3mg/ml at 37
o
C for 50 min, and re-fixated sections for 10 min in 4% PFA. Hybridization 
reaction of the LNA-probe was carried out in a Hybrite (Abbott Laboratories, IL) at 60
 o
C for 
5 min and 37
 o
C over night (12-18h). Immunological detection was done with anti-
DIG/alkaline phosphate conjugate (Enzo Diagnostics, NY) in a heater at 37
 o
C for 30 min and 
color reaction with NBT/BCIP (Enzo Diagnostics, NY) at 37
 o
C for 15-30 min, depending on 
when background coloring started to appear on the negative control (scrambled probe). The 
slides were then counterstained with nuclear fast red (Enzo Diagnostics, NY) to visualize the 
nuclei, before the slides finally were mounted. 
































































The detailed VEGF-A (rabbit polyclonal; RB-1678; Neomarkers, CA; 1:10) IHC procedure 
has been previously published.
17,20
 All TMA stainings were done in one single experiment. 
 
Scoring of ISH and IHC 
The ARIOL imaging system (Genetix, San Jose, CA) was used to scan the TMA slides of ISH 
staining. The slides were loaded in the automated loader (Applied Imaging SL 50) and 
specimens were scanned at low (1.25×) and high resolution (20×) using the Olympus BX 61 
microscope with an automated platform (Prior). Representative and viable tissue sections 
were scored manually and semiquantitatively for cytoplasmic staining on a computer screen. 
The dominant staining intensity in tumor cells was scored as: 0 = negative; 1 = weak; 2 = 
intermediate; 3 = strong (Figure 1). In case of disagreement (score discrepancy > 1), the slides 
were re-examined and a consensus was reached by the observers. In most cores there was a 
mixture of stromal cells and tumor cells. By morphological criteria only tumor cells were 
scored for staining intensity.  
All samples were anonymized and independently scored by one experienced 
pathologist and one technician (S.W.S. and K.L.). When assessing a variable for a given core, 
the observers were blinded to the scores of the other observer and to outcome. Mean score for 
each case was calculated from all four cores and both examiners. High expression of miR-126 
in tumor cells was defined as a mean score ≥ 2. For VEGF-A, the same cut-off value as 




































































All statistical analyses were done using the statistical package SPSS (Chicago, IL), version 
17. The Chi-square test and Fishers Exact test were used to examine the association between 
molecular marker expression and various clinicopathological parameters. The ISH scores 
from each observer were compared for interobserver reliability by use of a two-way random 
effect model with absolute agreement definition. The intraclass correlation coefficient 
(reliability coefficient) was obtained from these results. Plots of the disease-specific survival 
(DSS) according to marker expression were drawn using the Kaplan-Meier method, and 
statistical significance between survival curves was assessed by the log rank test. DSS was 
determined from the date of surgery to the time of lung cancer death. The multivariate 
analysis was carried out using the Cox proportional hazards model. Only variables of 
significant value from the univariate analysis were entered into the Cox regression analysis. 
The significance level used was P < 0.05. 
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Demographic, clinical, and histopathologic variables are shown in Table 1. The median age 
was 67 (range, 28-85) years and the majority of patients were male (76%). The NSCLC 
tumors comprised 191 squamous cell carcinomas (SCCs), 113 adenocarcinomas (ACs) and 31 
large-cell carcinomas (LCCs). There were 232 lymph node negative patients, while 103 
patients had lymph node metastasis. Due to nodal metastasis or non-radical surgical margins, 
59 (18%) patients received postoperative radiotherapy. 
 
Interobserver Variability 
Interobserver scoring agreement was tested for miR-126. The scoring agreement was good (r 
= 0.91, P < 0.001). 
 
Expression of miR-126 and Correlations 
miR-126 was expressed in the cytoplasm of most neoplastic tumor cells and to some lesser 
extent expressed in the cytoplasm of normal epithelial cells in lung tissue. Based on 
morphological criteria, inflammatory cells (macrophages, lymphocytes, granulocytes and 
plasma cells), pneumocytes and fibroblasts, normal as well as tumor associated, showed 
variable and in general slightly reduced cytoplasmic expression compared to tumor cells.  
There were no significant correlations between miR-126 expression levels and any of 
the clinicopathological variables except for histology (P = 0.039). There was a higher 
frequency of high miR-126 expression in SCCs (22.7%) compared to ACs (11.7%) and LCCs 
(10.7%) (P = 0.039). There was a weak, but significant, correlation between miR-126 and 
VEGF-A (r = 0.12, κ = 0.10, P = 0.037). In low respective high miR-126 expression group, 
the percentage of high VEGF-A expression was 41% and 57%.   































































Survival analyses according to clinicopathological variables are shown Table 1. Performance 
status (P = 0.013), histological differentiation (P < 0.001), surgical procedure (P < 0.004), 
pathological stage (P < 0.001), T-stage (P < 0.001), N-stage (P < 0.001) and vascular 
infiltration (P < 0.001) were all significant prognostic indicators for DSS. In the total material, 
miR-126 expression was a significant negative prognostic marker (Figure 2A, P = 0.005).  
Stratified by histology, high miR-126 expression was a significant negative prognostic 
marker in SCCs (Figure 2B, P < 0.001), but not in ACs (Figure 2C, P = 0.61) or LCCs (P = 
0.65). Stratified by nodal status, high miR-126 expression was significant associated with a 
poor prognosis in lymph node positive patients (Figure 2E, P<0.001), but not in lymph node 
negative patients (Figure 2D, P = 0.39).   
 
Multivariate Cox Proportional Hazard Analysis 
In the total material (Table 2), performance status (P = 0.027), pathological T-stage (P = 
0.001), N-stage (P < 0.001), histological differentiation (P = 0.038), vascular infiltration (P = 
0.01) and miR-126 (P = 0.028) were all independent prognostic factors.  
Stratified by histology, miR-126 was an independent negative prognostic factor (HR 
2.6, CI95% 1.5–4.5, P < 0.001) in SCCs. Stratified by lymph node status, miR-126 was 
independently associated with a dismal prognosis (HR 3.4, CI95%1.8–6.3, P<0.001) in lymph 
node positive patients. 
 
 
Co-expression VEGF-A and miR-126 
We have previously presented the prognostic impact of VEGF-A in the same tumor 
material.
17
 Herein, we have used the same cut-off value, but because of a survival update in 
2008 the follow-up time is prolonged. According to the tumor cell VEGF-A expression, the 5-






























































year survival rates were 48% (high expression, n =142) versus 66% (low expression, n =192) 
(P= 0.001) after the survival update. 
The co-expression of miR-126 and VEGF-A had a significant (P=0.002) prognostic 
impact in the univariate analysis (Figure 3) as low/low (n=150), mixed (n=129) and high/high 
(n=35) expression resulted in 5-year survival rates of 68%, 51% and 42%, respectively. In the 
multivariate analysis, these co-expressions of VEGF-A and miR-126 also had an independent 
prognostic impact (P=0.018). For patients with high VEGF-A/high miR-126 expression, HR 















































































We present the first large-scale study combining high-throughput TMA and in situ 
hybridization to evaluate the prognostic impact of miR-126 expression. In this unselected 
population of surgically resected NSCLC patients, high miR-126 expression is an independent 
negative prognostic factor in the total cohort. However, the prognostic impact is strongly 
related to those with SCCs or regional nodal metastasis. Moreover, there was a weak, 
although significant association between VEGF-A and miR-126 expression, and the co-
expression of VEGF-A and miR-126 was a strong independent negative prognostic factor.  
miRNAs are well preserved in formalin-fixed tissue, making them attractive 
candidates for use in routinely processed tissue materials.
22,23
 Most of the previous studies on 
miRNA expression were done on microarrays using RNA extracted from human cancer tissue 
samples, containing a mixture of neoplastic tumor cells and tumor related stromal cells. A 
major advantage of in situ hybridization is to precisely identify positive signals at the cellular 
level. For instance, recent data have demonstrated that some miRNAs had high expression 
levels in stromal cells but not in tumor cells.
24 
Using RNA extracts from whole tumors, this 
finding would easily be missed. As miR-126 often is down-regulated in tumor cells compared 
to stromal tissue, using RNA extracts may have led to erroneous results for this marker.  
To our knowledge, this is the first study to explore the prognostic impact of miR-126 







, and gastric cancer
11
 and was perceived a tumor 
suppressor, although, the prognostic impact was not addressed in these studies. Also in 
NSCLC, miR-126 has been interpreted as a tumor suppressor.
12-14
 In a combined in vitro and 
in vivo murine NSCLC study, Liu et al concluded that miR-126 inhibits VEGF-A expression. 
It should be noted that adenocarcinoma lung cancer cell lines were used in this study. 
Interestingly, we observe a significantly higher frequency of high miR-126 expression in 






























































SCCs when compared to ACs and LCCs, and the marker is a strong negative independent 
prognostic factor for the SCCs subgroup only. It is noteworthy that treatment responses and 
side effects from novel therapies have lately been correlated to NSCLC histology subgroups, 
and ACs and SSCs are increasingly recognized as different diseases instead of one. Regarding 
anti-angiogenic treatment in NSCLC, the VEGF monoclonal antibody, bevacizumab, is only 
given to non-SCCs due to the risk of fatal bleeding in SCCs.
25 
 
Supporting our findings, miR-126 is also found to be an important positive stimulator 
of angiogenesis.
5,26
 However, its angiogenic function has so far been mostly studied in the 
endothelial cells. In a comprehensive murine study, Wang et al observed miR-126 as an 
important player in angiogenesis. VEGF and fibroblast growth factor (FGF) binding to their 
respective receptors on endothelial cells leads to activation of the MAP kinase signaling 
pathway, which culminates in the nucleus to stimulate the transcription of genes involved in 
angiogenesis. miR-126 repress the expression of Spred-1, a negative regulator of Ras/MAP 
kinase signaling. Thus, loss of miR-126 function diminishes MAP kinase signaling in 




We observed a weak but significant correlation between high VEGF-A and high miR-
126 expression in the tumor cells, indicating that a similar connection may be present in the 
cancer cells. However, as there were several patients with high VEGF-A expression without 
high mir-126 expression, it indicates that miR-126 is only one of many potential VEGF-A 
regulators. Nevertheless, the co-expression of VEGF-A and miR-126 is independently 
associated with a poor prognosis.  
In the clinic, valid prognostic markers in the subpopulation of N+ patients are 
warranted. Among lymph node positive patients, high miR-126 expression was a strong 
independent negative prognostic factor. Indeed, 19 out of 21 N+ patients with high miR-126 






























































expression had a lung cancer related death within 5-years after diagnosis. Further studies are 
needed to address the question why miR-126 has such a strong prognostic impact in this 
subgroup. 
In conclusion, microRNAs are well preserved in formalin-fixed tissue, making them 
ideal candidates for investigation in routinely processed surgical specimens. miR-126 may 
stimulate angiogenesis through VEGF-A release from the tumor cells, but its prognostic 
impact seems to be highly tissue specific. miR-126 is a strong and independent prognostic 
factor in the total NSCLC cohort, but when stratified the prognostic impact is highly 
associated with SCCs patients or those with nodal metastasis. This may have significant 






































































Table 1. Prognostic Clinicopathologic Variables as Predictors for Disease-Specific Survival 












Age     0.34  
     ≤ 65 years 156 47 83 55  
     > 65 years 179 53 NR 60  
Sex     0.20 
     Female 82 25 190 63  
     Male 253 75 83 56  
Smoking     0.23 
     Never 15 5 19 43  
     Current 215 64 NR 60  
     Former  105 31 71 54  
Performance status     0.013 
     ECOG 0 197 59 NR 63  
     ECOG 1  120 36 64 52  
     ECOG 2 18 5 25 33  
Weight loss     0.71 
     < 10% 303 90 127 58  
     > 10% 32 10 98 57  
Histology     0.08 
     SCC 191 57 NR 66  
     Adenocarcinoma 113 34 54 45  
     LCC 31 9 98 56  
Differentiation     < 0.001 
     Poor 138 41 47 47  
     Moderate 144 43 190 64  
     Well 53 16 NR 68  
Surgical procedure     0.004 
     Lobectomy + Wedge* 243 73 190 61  
     Pneumonectomy 92 27 37 47  
Pathological stage     < 0.001 
     I 157 47 190 71  
     II 136 41 61 51  
     IIIa 42 12 17 23  
Tumor status     < 0.001 
     1 85 25 190 74  
     2 188 56 84 57  
     3 62 19 25 36  
Nodal status     < 0.001 
     0 232 69 190 66  
     1 76 23 35 43  
     2 27 8 18 18  
Surgical margins     0.29 
     Free 307 92 190 58  
     Not free 28 8 47 47  
Vascular infiltration     < 0.001 
     No 284 85 190 58  
     Yes 51 15 27 32  
NR, not reached 
* Wedge, n = 10 






































































Table 2. Results of the Cox regression analysis summarizing significant independent 











Tumor status   .001* 
     1 1.00   
     2 1.48 0.90 – 2.42 .12 
     3 2.65 1.53 – 4.61 .001 
    
Nodal status   <.001* 
     0 1.00   
     1 1.99 1.31 – 3.01 .001 
     2 3.36 1.95 - 5.79 <.001 
    
Differentiation   0.038* 
     Poor 1.00   
     Moderate 0.64 0.43 – 0.94 0.023 
     Well 0.58 0.31 – 1.09 0.088 
    
Performance status   .027* 
     Normal 1.00   
     Slightly reduced  1.66 1.13 – 2.43 .009 
     In bed < 50% 1.63 0.75 – 3.55 .22 
    
Vascular infiltration    
     No 1.00   
     Yes 1.85 1.16 – 2.96 .010 
    
miR-126  Tumor    
     Low 1.00   
     High 1.62 1.05 – 2.49 .028 
 




















































































LEGENDS OF FIGURES 
 
Fig. 1:  In situ hybridization (ISH) analysis of NSCLC representing strong and weak 
intensities for tumor cell miR-126 expression. Negative (scramble-miR) and positive (U6) 
controls from the same tissue area are shown. Strong miR-126 staining (A) with 
corresponding negative (C) and positive (E) controls to the left. Weak miR-126 staining (B) 
with corresponding negative (D) and positive (F) controls to the right. ISH positive signals 
(miR-126 and U6) stain blue, while nuclei stain red. 
 
Fig. 2: Disease-specific survival curves according to miR-126 expression in: (A) The total 
material; (B) Squamous cell carcinomas (SCCs); (C) Adenocarcinomas (ACs); (D) Lymph 
node positive patients; (E) Lymph node negative patients. 
 
Fig. 3: Disease-specific survival curves according to the co-expression of VEGF-A and miR-
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Fig. 1:  In situ hybridization (ISH) analysis of NSCLC representing strong and weak intensities for 
tumor cell miR-126 expression. Negative (scramble-miR) and positive (U6) controls from the same 
tissue area are shown. Strong miR-126 staining (A) with corresponding negative (C) and positive 
(E) controls to the left. Weak miR-126 staining (B) with corresponding negative (D) and positive (F) 
controls to the right. ISH positive signals (miR-126 and U6) stain blue, while nuclei stain red.  
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Fig. 2: Disease-specific survival curves according to miR-126 expression in: (A) The total material; 
(B) Squamous cell carcinomas (SCCs); (C) Adenocarcinomas (ACs); (D) Lymph node positive 
patients; (E) Lymph node negative patients.  
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Fig. 3: Disease-specific survival curves according to the co-expression of VEGF-A and miR-126 in 
335 resected NSCLC.  
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